Table 1. Clinical and demographic features in CS/CSL patients and KLLN promoter methylation.
| Characteristic | No. of patients | % Patients | Mean methylation % (SE) |
|---|---|---|---|
| Gender | |||
| Female | 779 | 77.0 | 13.9 (0.69) |
| Male | 233 | 23.0 | 15.7 (1.32) |
| P-value | 0.14 | ||
| Race/ethnicity | |||
| Caucasian | 594 | 58.7 | 13.6 (0.77) |
| African American | 29 | 2.87 | 15.8 (3.88) |
| Hispanic | 31 | 3.06 | 9.13 (2.46) |
| Other | 97 | 9.58 | 13.3 (1.90) |
| Unknown | 261 | 25.8 | 16.8 (1.34) |
| P-value | 0.12 | ||
| Age (years) | |||
| <18 | 160 | 15.8 | 13.7 (1.46) |
| 18–50 | 451 | 44.6 | 15.0 (0.97) |
| >50 | 401 | 39.6 | 13.7 (0.94) |
| P-value | 0.60 | ||
| CC score | |||
| ≤15 | 729 | 72.0 | 11.6 (0.65) |
| >15 | 282 | 27.9 | 21.3 (1.33) |
| P-value | <0.001 | ||
| PTEN status | |||
| Mut. negative | 564 | 55.7 | 11.0 (0.72) |
| Pathogenic mut. | 261 | 25.8 | 20.5 (1.36) |
| VUS | 187 | 18.5 | 15.6 (1.49) |
| P-value | <0.001 | ||
Note: Kruskal–Wallis rank-sum test was used to determine significance.